ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Investor conference call today, October 18th, at 8:30 a.m. E.T.
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatin... Biopharmaceuticals, OncologyARIAD Pharmaceuticals, Iclusig, ponatinib, chronic myeloid leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Conferences | Leukemia | Marketing | Pharmaceuticals